Overview

Radiation Toxicity Treatment Market is predicted to value over USD 5 billion by 2027 end with a CAGR of over 5.2% during the forecast period 2020 to 2027.

The rising installations of radiation therapy machines for treating different cancer types has increased radiation toxicity in patients. Furthermore, favourable reimbursements and government policies for cancer treatments has made radiation therapy ore accessible, thereby boosting the radiation toxicity treatment market growth. Moreover, the increased acceptance of factors that are colony stimulated shall boost the proliferation of the market. Additionally, parameters like positive product reviews, financials have bolstered the augmentation of the market. According to the American cancer Society, over 17,35,000 cancer cases were registered in 2018. Such a high prevalence of cancer shall increase the number of patients getting diagnosed with radiation toxicity, thereby propelling the market growth. Radiation toxicity is primarily caused by exposure to radiations in nuclear power plants either intentionally or accidently. With many countries investing in nuclear energy, there has been a rise in the number of nuclear plants, increasing the chances of people getting toxified by radiations, resulting in the augmentation of the market.

Market Segmentation:

By Product
•    Colony Stimulating Factors
•    Potassium Iodide
•    Prussian Blue 
•    Diethylenetriamine Pentaacetic Acid
•    Others
By Indication

• Acute Radiation Syndrome
• Bone Marrow Syndrome (Hematopoietic)
• Gastrointestinal Syndrome (GI)
• Cardiovascular (CV)
• Central Nervous System (CNS) Syndrome
• Chronic Radiation Syndrome

By Radiation

• Ionizing Radiation
• Alpha Radiation
• Beta Radiation
• Gamma Radiation
• Non-Ionizing Radiation

By End User 
•    Hospitals
•    Research & Academic Institutes
By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

The market is diversified into product, by indication, by radiation, by end user and region. The product segment is fragmented into colony stimulating factors, potassium iodide, prussian blue, diethylenetriamine pentaacetic acid. The end user segment is classified into hospitals, research & academic institutes.

Regional Analysis:

The North America region is predicted to hold the largest radiation toxicity treatment market share during the forecast period owing to increased use of PET and single-photon emission computed tomography scanning machines at diagnostic centres. Furthermore, favourable health coverage policies and stringent regulations have boosted the market growth in the region. The Asia pacific region, on the other hand, is predicted to grow at a substantial rate during the forecast period. 

Competitive Landscape:                            

Some of the key market players are Aeolus Pharmaceuticals, Cantex Pharmaceuticals, Gamida Cell Ltd., Nanotherpautics Inc., NeoStem Inc., Cleveland BioLabs Inc., Osiris Therapeutics Inc., Amgen Inc., Partner Therapeutics, Inc., Novartis AG.

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global radiation toxicity treatment market by product, by indication, by radiation, by end user and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
        1.1. Objectives of the Study 
        1.2. Market Definition 
        1.3. Market Scope 
               1.3.1. Years Considered for the Study
               1.3.2. Market Covered
        1.4. Currency 
        1.5. Limitations 
        1.6. Stakeholders 
 2.  Research Methodology 
        2.1. Research Data 
               2.1.1. Secondary Data
                          2.1.1.1. Key Data from Secondary Sources
               2.1.2. Primary Data
         2.1.2.1. Key Data from Primary Sources
        2.2. Market Size Estimation 
        2.3. Market Breakdown and Data Triangulation 
        2.4. Assumptions for the Study  
3. Executive Summary
        3.1. Market Outlook
        3.2. Segment Outlook
        3.3. Competitive Insights
4. Global Radiation Toxicity Treatment Market Variables, Trends & Scope
        4.1. Market Lineage Outlook
        4.2. Penetration and Growth Prospect Mapping
        4.3. Industry Value Chain Analysis
        4.4. Cost Analysis Breakdown
        4.5. Technology Overview
        4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Radiation Toxicity Treatment Market Overview
        5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Radiation Toxicity Treatment Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Radiation Toxicity Treatment Market Analysis Tools
        6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
        6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
        6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
        6.4. Market Entry Strategies
        6.5. Case Studies
7. Global Radiation Toxicity Treatment Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million)
        7.1 Colony Stimulating Factors
        7.2 Potassium Iodide
        7.3 Prussian Blue 
        7.4 Diethylenetriamine Pentaacetic Acid
        7.5 Others  
8. Global Radiation Toxicity Treatment Market, By Indication Historical Analysis and Forecast 2020-2027 (USD Million)
        8.1. Acute Radiation Syndrome
                8.1.1. Bone Marrow Syndrome (Hematopoietic)
                8.1.2. Gastrointestinal Syndrome (GI)
                8.1.3. Cardiovascular (CV)
                8.1.4. Central Nervous System (CNS) Syndrome
        8.2. Chronic Radiation Syndrome
9. Global Radiation Toxicity Treatment Market, By Radiation Historical Analysis and Forecast 2020-2027 (USD Million)
        9.1. Ionizing Radiation
                9.1.1. Alpha Radiation
                9.1.2. Beta Radiation
                9.1.3. Gamma Radiation
        9.2. Non-Ionizing Radiation
10. Global Radiation Toxicity Treatment Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
        10.1. Hospitals        
        10.2. Research & Academic Institutes
11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        11.1. Introduction
        11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  11.2.1. U.S.A
                  11.2.2. Canada
                  11.2.3. Mexico
        11.3. Market Size (USD Million) Forecast for North America 2020-2027 
12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        12.1. Introduction
        12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                 12.2.1. Brazil
                 12.2.2. Venezuela
                 12.2.3. Argentina
                 12.2.4. Rest of Latin America
        12.3. Market Size (USD Million) Forecast for Latin America 2020-2027  
13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        13.1. Introduction
        13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  13.2.1. Germany
                  13.2.2. U.K
                  13.2.3. France
                  13.2.4. Italy
                  13.2.5. Spain
                  13.2.6. Russia
                  13.2.7. Poland
                  13.2.8. Rest of Europe
        13.3. Market Size (USD Million) Forecast for Europe 2020-2027
14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        14.1. Introduction
        14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  14.2.1. Japan
                  14.2.2. China
                  14.2.3. India
                  14.2.4. Australia and New Zealand
                  14.2.5. ASEAN
                  14.2.6. Rest of Asia Pacific
        14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        15.1. Introduction
        15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  15.2.1. Saudi Arabia
                  15.2.2. UAE
                  15.2.3. South Africa
                  15.2.4. Egypt
        15.3. Market Size (USD Million) Forecast for MEA 2020-2027           
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    16.1 Aeolus Pharmaceuticals
            16.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.1.2. Product Portfolio
            16.1.3. SWOT Analysis
            16.1.4. Financial Overview
            16.1.5. Strategic Overview
    16.2 Cantex Pharmaceuticals
            16.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.2.2. Product Portfolio
            16.2.3. SWOT Analysis
            16.2.4. Financial Overview
            16.2.5. Strategic Overview
    16.3 Gamida Cell Ltd.
            16.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2. Product Portfolio
            16.3.3. SWOT Analysis
            16.3.4. Financial Overview
            16.3.5. Strategic Overview
    16.4 Nanotherpautics Inc.
            16.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.4.2. Product Portfolio
            16.4.3. SWOT Analysis
            16.4.4. Financial Overview
            16.4.5. Strategic Overview
    16.5 NeoStem Inc.
            16.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.5.2. Product Portfolio
            16.5.3. SWOT Analysis
            16.5.4. Financial Overview
            16.5.5. Strategic Overview
    16.6 Cleveland BioLabs Inc.
            16.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.6.2. Product Portfolio
            16.6.3. SWOT Analysis
            16.6.4. Financial Overview
            16.6.5. Strategic Overview
    16.7 Osiris Therapeutics Inc.
            16.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.7.2. Product Portfolio
            16.7.3. SWOT Analysis
            16.7.4. Financial Overview
            16.7.5. Strategic Overview
    16.8 Amgen Inc.
            16.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.8.2. Product Portfolio
            16.8.3. SWOT Analysis
            16.8.4. Financial Overview
            16.8.5. Strategic Overview
    16.9 Partner Therapeutics, Inc.
            16.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.9.2. Product Portfolio
            16.9.3. SWOT Analysis
            16.9.4. Financial Overview
            16.9.5. Strategic Overview
    16.10 Novartis AG
            16.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.10.2. Product Portfolio
            16.10.3. SWOT Analysis
            16.10.4. Financial Overview
            16.10.5. Strategic Overview
17 Impact of COVID-19
      17.1. Positive influence on the healthcare industry
      17.2. The financial disruption of the manufacturing sector
      17.3. Impact of COVID-19 on emerging companies
      17.4. Significant mandates in the healthcare regulations initiated by administrations
      17.5. The overall economic slowdown of the developing and developed nations
18. Competitive Intelligence and Competitive Matrix
      18.1 Competitive Intelligence
      18.2 Competitive Matrix
19. Major Deals and Strategic Alliances Analysis
      19.1 Joint ventures
      19.2 Mergers and acquisitions
      19.3 Licensing and partnerships 
      19.4 Technology Collaborations
      19.5 Strategic Divestments
      19.6 Market Entry Strategies                  
20. Relevant Case Studies and Latest News Updates     
21. Key Market Takeaway Points from the Market Analysts at Future Market Analytic

Tables

Figures